Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
May 29th 2008
Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR™ with Dr. Stephan Mielke and...
read more 
(NL version)
(NL version)
Kiadis Pharma receives Orphan Drug Designation for Rhitol™ from the FDA
Apr 15th 2008
Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol™ Orphan Drug...
read more (NL version)
(NL version)
Promising clinical data from Kiadis Pharma’s lead product ATIR™ presented by NIH investigators
Mar 25th 2008
Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained so far in a physician initiated clinical study for ATIR™ led...
read more (NL version)
(NL version)
Kiadis Pharma Press Releases
Kiadis Pharma Press Releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.
Feb 22nd 2008
Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™
(NL version)
Jan 31st 2008
Dec 19th 2007
Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc
(NL version)
Dec 14th 2007
ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments
(NL version)
Nov 28th 2007
Nov 23rd 2007
Nov 19th 2007
Kiadis Pharma continues to provide Rhitol to participating physicians during completion of current clinical study
(NL version)
Nov 7th 2007
Oct 10th 2007
Aug 31st 2007
Aug 17th 2007
Jul 21st 2007
Jul 9th 2007
Jun 26th 2007
Mar 28th 2007
Feb 12th 2007
Jan 19th 2007
Dec 13th 2006
Dec 12th 2006
Dec 11th 2006
Nov 28th 2006
